ライフサイエンスコーパス: Kirsten

1 Kirsten rat sarcoma viral oncogene (KRAS) mutations are

2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is the

3 Kirsten rat sarcoma viral oncogene homologue (KRAS) is a

4 Kirsten rat sarcoma virus (KRAS)-G12C inhibition causes

5 Kirsten rat sarcoma virus (KRAS)-mutant colorectal cance

6 Kirsten-Ras (K-Ras) knockout fibroblasts express undetec

7 s in codons 248 and 273 of TP53 and codon 12 Kirsten-ras (KRAS) are commonly found in human carcinoma

8 fic TM isoforms in transformed cells using a Kirsten virus-transformed cell line (ATCC NRK1569) as a

9 red with those expressing G35 to A activated Kirsten ras.

10 ne kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers,

11 epidermal growth factor receptor (EGFR) and Kirsten ras (KRAS) confer sensitivity and resistance, re

12 over-expression of both wild-type Harvey and Kirsten Ras proteins as contributors to rat mammary carc

13 serine/threonine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) m

14 itical relationship between EGFR, c-MYC, and Kirsten rat sarcoma virus (K-Ras), simultaneous degradat

15 Oncogenic mutations in B-Raf and Kirsten-Ras (K-Ras) are mutually exclusive during human

16 Targeted approaches, such as Kirsten rat sarcoma (KRAS) inhibition, have shown promis

17 s not present in human neutrophils, but both Kirsten-ras (K-ras) and Neuronal-ras are.

18 s: A cluster randomised controlled trial" by Kirsten Corder and colleagues.

19 Elevated expression of either c-Kirsten A-Ras or c-Kirsten B-Ras did not reverse the apo

20 ed expression of either c-Kirsten A-Ras or c-Kirsten B-Ras did not reverse the apoptotic sensitivity

21 We additionally compared Kirsten rat sarcoma viral oncogene homolog (KRAS) mutati

22 Cxcr2 ligands expressing Kirsten rat sarcoma (KRAS-PDAC) cells were orthotopicall

23 Exclusive activation of either the Harvey-, Kirsten-, or N-ras gene is often found in human and rode

24 Loss of Kdm6a in Kirsten rat sarcoma virus (K-RAS)-transformed murine fib

25 start, the combination of sotorasib, a KRAS (Kirsten rat sarcoma viral oncogene homolog)-G12C inhibit

26 and SCC, including the proto-oncogenes KRAS (Kirsten rat sarcoma viral proto-oncogene) and KIT (KIT p

27 1 (lung adenoma susceptibility 1) and Kras2 (Kirsten rat sarcoma oncogene 2) genes as primary candida

28 n 0.5 Mb in which at least two genes, Kras2 (Kirsten rat sarcoma oncogene 2) and Casc1 (cancer suscep

29 nesylation and carboxymethylation of KRAS4b (Kirsten rat sarcoma isoform 4b) are essential for its in

30 dermal growth factor receptor (EGFR), mutant Kirsten rat sarcoma viral oncogene homolog (Kras), or ov

31 Cs are enriched after chemotherapy in mutant Kirsten rat sarcoma viral oncogene homolog (Kras) colore

32 The 40-year desire to target the mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) therapeutically

33 ide targets of covalent inhibitors to mutant Kirsten rat sarcoma (KRAS)(G12C) and Bruton's tyrosine k

34 Notably, Kirsten rat sarcoma (KRAS)-driven tumors have been repor

35 Expression of Kirsten rat sarcoma viral oncogene [Kras(G12V)] and disr

36 take at the single-cell level in the lung of Kirsten rat sarcoma virus-driven cancer mouse models usi

37 ell (EC) expression of activating mutants of Kirsten rat sarcoma virus (kRas), mitogen-activated prot

38 ene derivatives bind to transient pockets on Kirsten-Ras (K-Ras) and inhibit GDP-GTP exchange.

39 Oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutati

40 lung cancer based on activation of oncogenic Kirsten rat sarcoma viral oncogene homolog (Kras) and lo

41 Aberrant expression of the oncogenic Kirsten-Ras (Ki-Ras) and interferon-stimulated gene 15 (

42 rm to identify fragment ligands to oncogenic Kirsten rat sarcoma (KRas).

43 y syndrome coronavirus 2), and oncoproteins (Kirsten rat sarcoma virus, paired-like homeobox 2b and N

44 e activated or wild-type forms of Harvey- or Kirsten-ras.

45 hoshatase and tensin homolog (PTEN) loss, or Kirsten rat sarcoma virus (KRAS) overexpression.

46 K-Ras (Kirsten-rat sarcoma viral oncogene homolog) is a promine

47 Of the three different isoforms of Ras (Kirsten, Harvey, and Neural), we previously demonstrated

48 Here, we probe three isoforms of RAS [Kirsten Rat Sarcoma viral oncogene (KRAS), Harvey Rat Sa

49 noma (PDAC) involves activation of c-Ki-ras2 Kirsten rat sarcoma oncogene homolog (KRAS) signaling, b

50 The vi-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) represents one

51 Directly targeting oncogenic V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-Ras) with

52 se (ALK), EGF receptor (EGFR), and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) are ma

53 imaging to provide a signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) gene m

54 Additional activation of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) networ

55 viral oncogene homolog B1 (BRAF), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), or ep

56 kers were associated with non-pCR; v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation (P =

57 h both tumor protein p53 (p53) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations had

58 her, in patients with both p53 and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutations or

59 K-RAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene) gene was predicted a

60 Finally, proximal proteomics reveals Kirsten rat sarcoma virus (KRAS), but not Harvey rat sar

61 Novel inhibitors targeting Kirsten rat sarcoma virus homolog (KRAS) KRAS(G12C) in v

62 ey ras expression was 1.5-2-fold higher than Kirsten ras or N-ras at each adult stage of development,

63 A-interference technology, we delineate that Kirsten rat sarcoma oncogene (KRAS)-activated mitogen-ac

64 The Kirsten rat sarcoma viral oncogene homologue KRAS is amo

65 Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) protei

66 Activating mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) underl

67 Mutations in the Kirsten-ras (K-ras) oncogene occur early and frequently

68 th colorectal liver metastases (CRLM) is the Kirsten rat sarcoma viral oncogene homolog (KRAS); howev

69 carrying either three or seven copies of the Kirsten ras gene under the same promoter (HrKr) were pro

70 or that targets the elusive aspartate of the Kirsten rat sarcoma viral oncogene homolog (K-Ras)-G12D

71 er a (Clec9a) locus causes expression of the Kirsten rat sarcoma viral oncogene homolog (Kras)(G12D)

72 Neural), we previously demonstrated that the Kirsten isoform is key in the control of renal fibroblas

73 To examine whether the Kirsten rat sarcoma viral oncogene homolog (KRAS)-varian

74 survival disadvantage, especially within the Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant

75 orexin receptor 1 (HcrtR1/OX(1)R) but not to Kirsten murine sarcoma virus transformed rat kidney epit

76 atinum chemotherapy were stratified by tumor Kirsten rat sarcoma virus homolog (KRAS) mutation status

77 Methods: Two Kirsten rat sarcoma virus-driven lung cancer mouse model

78 sing wild-type Harvey ras, but not wild-type Kirsten ras.

79 nitumumab on cell lines expressing wild-type Kirsten-Ras (K-Ras) and oncogenic K-Ras mutations.

80 ostate epithelial cells transformed by viral Kirsten-ras (267B1/Ki-ras cells) compared with those in

81 ently mutated oncogene in human cancer, with Kirsten rat sarcoma (KRAS) being the most commonly mutat

82 erall survival was found among patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutate

83 oint has already been reported.Patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutate

84 Patients with Kirsten rat sarcoma viral oncogene homologue (KRAS)(G12C

85 patients with colorectal cancer, tumors with Kirsten rat sarcoma viral oncogene (KRAS) or B-rapidly a